[144] Datadog, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 filed for Arteris, Inc. (AIP) discloses that insider Nicholas Hawkins plans to sell 11,276 common shares on 5 Aug 2025 through Morgan Stanley Smith Barney. The shares are valued at $106,558, implying an estimated price of roughly $9.46 each. Arteris has 41.98 million shares outstanding, so the proposed sale equals ~0.03 % of the float.

The filing also details the insider’s trading activity over the prior three months: 60,324 shares have already been sold under a Rule 10b5-1 plan, generating about $488 k in gross proceeds. These prior disposals occurred on 13 separate dates between 8 May 2025 and 1 Aug 2025, with individual block sizes ranging from 438 to 11,000 shares.

All shares being sold were acquired via stock-option exercises on 18 Oct 2021 and paid for in cash. The signer certifies no undisclosed material adverse information. While the absolute number of shares is small relative to Arteris’s capitalization, the steady cadence of insider selling may draw investor attention to management’s sentiment and share-based compensation practices.

Positive

• Rule 10b5-1 plan mitigates concerns about trading on non-public information
• Sale size is only ~0.03 % of shares outstanding, posing negligible dilution or market impact

Negative

• Continued insider selling (>60 k shares in past 3 months plus new 11 k notice) may signal limited insider confidence
• Aggregate proceeds ~$0.6 M in a short window could pressure sentiment in the absence of offsetting insider buys

Insights

Corporate Governance Expert

TL;DR: Multiple 10b5-1 sales and new Form 144 indicate ongoing insider monetization, mildly negative for sentiment.

The filing signals continued disposal of shares by Nicholas Hawkins. Although Rule 10b5-1 plans reduce the risk of information asymmetry, the cumulative sale of >60 k shares in three months plus a fresh 11 k-share notice may be interpreted as waning insider confidence or simple diversification. The amount is immaterial to the float, but frequent filings keep insider-selling headlines alive, which can pressure the stock in low-liquidity periods. No red flags regarding undisclosed adverse information are claimed.

Portfolio Manager

TL;DR: Transaction is immaterial to fundamentals; treat as neutral unless insider selling trend accelerates.

At 0.03 % of outstanding shares and ~$0.1 M value, this planned sale will not affect supply-demand dynamics. Arteris trades millions of dollars daily, so execution risk is minimal. Investors should monitor if other executives follow suit or if Hawkins’s remaining holdings shrink materially. Absent macro context or earnings data, the event is not impactful to valuation models but could weigh on short-term sentiment.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	41468	5769442.84	319498060	08/05/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common	08/05/2025	Exercise of Stock Options	Issuer			41468	08/05/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ALEXIS T LEQUOC 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	07/14/2025	41468	5775376.62
10b5-1 Sales for ALEXIS T LEQUOC 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	06/04/2025	127105	15247350.56
ALEXIS T LEQUOC 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	06/02/2025	13766	1608433.21
10b5-1 Sales for ALEXIS T LEQUOC 620 8th Avenue, 45th Floor New York NY 10018	Class A Common	05/07/2025	127105	13451674.68

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Arteris (AIP) shares are planned for sale in this Form 144?

The filing covers 11,276 common shares scheduled for sale on 5 Aug 2025.

What is the estimated value of the planned insider sale?

At an implied price of ~$9.46, the sale is valued at about $106,558.

How much has the insider already sold in the past 3 months?

Nicholas Hawkins sold 60,324 shares between 8 May 2025 and 1 Aug 2025, raising roughly $488 k.

Does the sale rely on a Rule 10b5-1 trading plan?

Yes. The prior sales and the new notice reference a 10b5-1 plan for pre-arranged trades.

What percentage of Arteris’s outstanding shares does the new sale represent?

Approximately 0.03 % of the 41.98 million shares outstanding.

Were the shares purchased or option-derived?

All shares were acquired through stock-option exercises on 18 Oct 2021 and paid for in cash.